Blueprint Medicines (NASDAQ: BPMC) reported Q1 EPS of ($1.29), $0.16 worse than the analyst estimate of ($1.13). Revenue for the quarter came in at $954 thousand versus the consensus estimate of $2.77 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.